The observed effect was robust in sensitivity analyses and independent of fibrate dose .
The present meta- analysis suggests that fibrate therapy increases circulating levels of adiponectin .
BACKGROUND Several lines of evidence have indicated the insulin-sensitizing , anti-diabetic and anti-atherosclerotic properties of adiponectin , as well as the inverse association between circulating levels of this adipokine and development of cardiovascular outcomes .
Improvement of adiponectin status has been reported as a pleiotropic effect of fibrate therapy , but the findings have not been conclusive .
OBJECTIVE To systematic ally review and meta-analyze available evidence from r and omized placebo-controlled trials ( RCTs ) on the impact of fibrate therapy on circulating levels of adiponectin .
Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia.
BACKGROUND We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles . METHODS A r and omized , single-blind , placebo-controlled , cross-over study was conducted in 53 patients with primary hypertriglyceridemia . We administered placebo or fenofibrate 160 mg daily for 8 weeks . RESULTS When compared with placebo , fenofibrate therapy substantially lowered plasma levels of TNF-α by 6±3 % ( P=0.014 ) and hsCRP from 1.10 to 0.90mg/l ( P=0.004 ) . When compared with placebo , fenofibrate therapy increased plasma levels of adiponectin by 17±4 % ( P=0.001 ) , insulin sensitivity by 4±1 % ( as assessed by QUICKI , P=0.009 ) , and decreased plasma levels of leptin and resistin by 4±7 % ( P=0.022 ) and 10±3 % ( P=0.001 ) , respectively . There were correlations between percent changes in QUICKI and percent changes in adiponectin levels ( r=0.279 , P=0.043 ) or leptin ( r=-0.280 , P=0.042 ) . CONCLUSIONS Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients
The observed effect was robust in sensitivity analyses and independent of fibrate dose .
The present meta- analysis suggests that fibrate therapy increases circulating levels of adiponectin .
BACKGROUND Several lines of evidence have indicated the insulin-sensitizing , anti-diabetic and anti-atherosclerotic properties of adiponectin , as well as the inverse association between circulating levels of this adipokine and development of cardiovascular outcomes .
Improvement of adiponectin status has been reported as a pleiotropic effect of fibrate therapy , but the findings have not been conclusive .
OBJECTIVE To systematic ally review and meta-analyze available evidence from r and omized placebo-controlled trials ( RCTs ) on the impact of fibrate therapy on circulating levels of adiponectin .